Patient experiences following Parkinson’s disease treatment with inhaled levodopa: Results from a Phase 2b study
Objective: To report patient experiences from a clinical trial investigating Parkinson's disease (PD) control following treatment with inhaled levodopa. Background: CVT-301, an inhaled levodopa powder…Acute admissions in people with Parkinson’s – More than just frailty
Objective: Review if admissions of People with Parkinson's(PwP) to hospital is directly related to their Parkinson's symptoms. Assess if medications are received on time. Explore…Effects of pyridostigmine bromide vs. fludrocortison in the treatment of orthostatic hypotension in Parkinson’s disease
Objective: To report results of an investigator-initiated trial to show the non-inferiority of pyridostigmine bromide (PB) vs. fludrocortisone (FC) in the treatment of symptomatic orthostatic…Can hospital admissions predict mortality in Parkinson’s?
Objective: Profile patients with Parkinson's who experience inpatient care. Assess the impact of admissions to hospital and evaluate readmissions and mortality rates. Background: People with…Taking specialist clinics into community nursing homes
Objective: Evaluate the effectiveness of delivering specialist Parkinson's care in community care home settings. Background: Our drive to improve older people's care has led to…Medication use patterns vary across expert Parkinson’s disease clinics
Objective: This analysis aims to describe and quantify the medication patterns for patients with Parkinson's disease (PD) managed in expert clinics. Background: Antiparkinson medication use…Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations
Objective: Two Phase 2 studies were conducted to evaluate the safety profile of inhaled CVT-301 administered to Parkinson's disease (PD) patients with motor fluctuations. Background:…Status of NPF-QII after six years: Updates to the dataset
Objective: To describe the status and recent findings from the National Parkinson Foundation's Quality Improvement Initiative (NPF-QII), an 8,179 subject observational clinical study conducted at…Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations
Objective: To review the clinical use of a newer extended-release levodopa preparation in 50 consecutive patients with PD experiencing motor fluctuations on immediate-release levodopa. Background:…Evaluation of droxidopa dosing and clinical response in 50 consecutive patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension
Objective: To determine the effect of droxidopa on clinical symptoms and standing systolic blood pressure in patients with Parkinson's disease (PD) and neurogenic orthostatic hypotention…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.